Beta Amyloid News and Research

RSS

Researchers discover how red wine may reduce Alzheimer's

Scientists call it the "French paradox" - a society that, despite consuming food high in cholesterol and saturated fats, has long had low death rates from heart disease.

21 Nov 2008

Light drinking has certain health benefits, researchers look at why

While the physiological damage and social havoc created by alcohol abuse and dependency are well-known, it is also true that light-to-moderate drinking has certain health benefits.

20 Nov 2008

Prana Biotechnology's compound could halt Alzheimer's pathology

Prana Biotechnology has announced that a recent independent study conducted by Massachusetts General Hospital (MGH) has demonstrated that the Company's Metal-Protein Attenuating Compounds (MPACs) could halt Alzheimer's pathology.

19 Nov 2008

Study looks at investigational compound MK-677 in Alzheimer's disease

A new study shows that a drug that increases the release of growth hormone failed to slow the rate of progression of Alzheimer's disease in humans.

17 Nov 2008

Greater thinking, learning and memory abilities delay symptoms of Alzheimer's disease

Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer's disease, according to a report in the November issue of Archives of Neurology , one of the JAMA/Archives journals.

10 Nov 2008

Education lessens the effects of Alzheimer's

The scientists from the Washington University School of Medicine, St. Louis, say their research supports the 'cognitive reserve' hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer's disease.

10 Nov 2008

Nicotinamide, a form of vitamin B3, reduces Alzheimer's symptoms

An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.

5 Nov 2008

Self assembling "organic wires"

From pacemakers constructed of materials that so closely mimic human tissues that a patient's body can't discern the difference to devices that bypass injured spinal cords to restore movement to paralyzed limbs, the possibilities presented by organic electronics read like something from a science fiction novel.

23 Oct 2008

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

2 Oct 2008

PET scans spot signs of early Alzheimer's

Scientists in Finland say a type of imaging technique known as positron emission tomography (PET) scanning may be a useful and non-invasive way of diagnosing the early stages of Alzheimer’s disease.

11 Aug 2008

Promising new therapy for Alzheimer's

NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin (IGIV) for Alzheimer's disease at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago.

From Baxter International Inc. 30 Jul 2008

Markers in blood and spinal fluid, and a new imaging agent, show promise for early detection of Alzheimer's

With the continued aging of the population and the growing epidemic of Alzheimer's, early detection of the disease is crucial for risk assessment, testing new therapies, and eventual early intervention with better drugs, once they are developed. Four studies reported today at the Alzheimer's Association's 2008 International Conference on Alzheimer's Disease (ICAD 2008) in Chicago bring us closer to that goal of early detection by describing advances in biomarkers.

29 Jul 2008

Tethered bilayer membrane may unlock secrets of early-stage Alzheimer's

Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer's disease actually impairs a neuron's structure and function.

23 Jul 2008

Potentially new biomarkers for Alzheimer's

Every aging baby boomer listens for the footsteps of Alzheimer's, and for good reason: It's estimated that 10 million American boomers will develop the disease. The need to develop preventative strategies, ideally long before Alzheimer's destructive, clinical symptoms appear, is critical.

19 Jul 2008

AFFiRiS GmbH alzheimer's vaccine progress

In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an innovative Alzheimer's vaccine (AFFITOPE AD01).

16 Jul 2008

Novel drug ionophore shows potential for Alzheimer's

Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).

10 Jul 2008

Neuron to publish Prana's PBT2 preclinical research on Alzheimer's disease

Prana Biotechnology Ltd. has announced the publication of key research findings with its lead Alzheimer's Disease drug, PBT2.

10 Jul 2008

Transgenic tomatoes as edible vaccine carriers for Alzheimer's disease

The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer's disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University.

8 Jul 2008

Low levels of high-density lipoproteins linked to memory loss, dementia risk

Low levels of high-density lipoproteins (HDL) - the "good" cholesterol - in middle age may increase the risk of memory loss and lead to dementia later in life, researchers reported in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

30 Jun 2008